Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
Junjing Yin, Xia Zhou, Xuemei Li, Chenglu Yuan, Xiaoxia Chu, Lumei Hao, Hongying Wu, Yuping Zhong · 2024
Read Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease by Junjing Yin, Xia Zhou, Xuemei Li, Chenglu Yuan, Xiaoxia Chu, Lumei Hao, Hongying Wu, Yuping Zhong (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11573974.txt.
Description
Junjing Yin and seven co-authors tested a four-drug regimen in ten patients with newly diagnosed multiple myeloma that had spread beyond the bone marrow, in this 2024 study. This extramedullary form answers treatment poorly. The regimen added selinexor to the standard trio of bortezomib, lenalidomide, and dexamethasone, followed by a two-drug maintenance phase.
Every patient responded. Four reached complete remission or better, and four more had very good partial responses. Neither average survival nor time without progression had been reached when the authors wrote. Low platelet counts were the main serious side effect, and the rest were mild and manageable. The authors call the combination effective and tolerable for this hard subgroup.
Catalog record
| CREATOR | Junjing Yin, Xia Zhou, Xuemei Li, Chenglu Yuan, Xiaoxia Chu, Lumei Hao, Hongying Wu, Yuping Zhong |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |